An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy

Chen, Yichao; Xia, Rui; Huang, Yixian; Zhao, Wenchen; Jiang, Li; Zhang, Xiaolan; Wang, Pengcheng; Venkataramanan, Raman; Fan, Jie; Xie, Wen; Ma, Xiaochao; Lu, Binfeng; Li, Song

doi:10.1038/ncomms13443

Cited by 168 publications

(145 citation statements)

References 36 publications

Supporting

Mentioning

139

Contrasting

Order By: Relevance

“…These multifunctional nanocarriers not only boosted the apoptosis of cervical cancer cells compared with free cisplatin but also dramatically decreased the production of Kyn to simultaneously potentiate effector T cell differentiation in the tumor microenvironment. These data are in accordance with reported findings …”

Section: Delivery System For Provoking Antitumor Immunitysupporting

confidence: 94%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid‐moving advances of nanoparticle‐based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.

show abstract

Section: Delivery System For Provoking Antitumor Immunitysupporting

confidence: 94%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

show abstract

“…Synthetic micelles have been used to either directly modulate the immune system as a part of a combinatorial approach to reduce tumor burden or as a vaccine nanocarrier against cancer and other ailments. As an immunomodulatory vehicle, several types of synthetic micelles have been developed, including: i) a PEG‐PLGA‐based micelle with collagen IV‐targeting peptides to deliver the anti‐inflammatory peptide (Ac2‐26) to exert tissue‐restorative properties to the vascular basement membrane, ii) a monomethyl PEG–PCL micelle to envelope and deliver fisetin for activating cell surface death receptors in colon tumors, iii) an acid‐activatable cationic micelle encapsulating photosensitizers for combinatorial PDT and siRNA delivery to knockdown PD‐L1 expression, and iv) a PEG‐prodrug (NLG919, an IDO inhibitor) conjugate‐based micelle to reduce tumor‐associated immunosuppression and improve outcomes when combined with systemic paclitaxel . Monomethyl PEG–PCL micelles have also been used to encapsulate NLG919 and photosensitizers for PTT, activating antigen‐specific CTLs and generating abscopal effects …”

Section: Nanoscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell‐mediated transport and serve as artificial antigen‐presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

show abstract

“…Other than the common application of PD‐1 in combinational therapy, incorporating IDO inhibitors into chemotherapy has also became attractive because of the dramatic boost of conventional cancer chemotherapeutics. Y. C. Chen et al () introduced a co‐delivery system with PTX encapsulated in a nanomicellar carrier grafting the IDO inhibitor of NLG919 (PEG 2k ‐Fmoc‐NLG) as combination therapy. Outcomes in 4T1.2 cancer and B16 melanoma mice models indicated that the co‐delivery of PTX and NLG919 provided stronger antitumor efficiency.…”

Section: Combinational Cancer Immunotherapy With Nanoparticlesmentioning

confidence: 99%

Nanotechnology platforms for cancer immunotherapy

Yang

Zhao

et al. 2019

WIREs Nanomed Nanobiotechnol

104

View full text Add to dashboard Cite

Various cancer therapies have advanced remarkably over the past decade. Unlike the direct therapeutic targeting of tumor cells, cancer immunotherapy is a new strategy that boosts the host's immune system to detect specific cancer cells for efficient elimination. Nanoparticles incorporating immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance antitumor immunity. Such nanoparticle‐based cancer immunotherapies have received considerable attention and have been extensively studied in recent years. This review thus focuses on nanoparticle‐based platforms (especially naturally derived nanoparticles and synthetic nanoparticles) utilized in recent advances; summarizes delivery systems that incorporate various immune‐modulating agents, including peptides and nucleic acids, immune checkpoint inhibitors, and other small immunostimulating agents; and introduces combinational cancer immunotherapy with nanoparticles, especially nanoparticle‐based photo‐immunotherapy and nanoparticle‐based chemo‐immunotherapy. Undoubtedly, the recent studies introduced in this review prove that nanoparticle‐incorporated cancer immunotherapy is a highly promising treatment modality for patients with cancer. Nonetheless further research is needed to solve safety concerns and improve efficacy of nanoplatform‐based cancer immunotherapy for future clinical application. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy

Cited by 168 publications

References 36 publications

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Materials for Immunotherapy

Nanotechnology platforms for cancer immunotherapy

Contact Info

Product

Resources

About